The U.S. oncology market, valued at $81.34 billion in 2025, is projected to reach $211.78 billion by 2034, growing at a CAGR of 11.75%, according to a report by Towards Healthcare, a healthcare and life science research & business consulting firm. There have been many therapeutic advancements in oncology, from chemotherapy to tyrosine kinase inhibitors and monoclonal antibodies. The top-selling cancer drug, Keytruda, developed by Merck, is a monoclonal antibody.
The company we are profiling today is Bicycle Therapeutics plc (BCYC), which is developing drugs with the potential to be the next major transformative solution in oncology.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.